Quinacrine sterilization (QS) in a private practice in Daytona Beach, Florida: a preliminary report.
To affirm that WS can be performed safely and effectively in a U.S. private office practice. The U.S. FDA Modernization Act of 1997 Pharmacy Compounding Provisions made it possible for American physicians to begin offering WS to their patients. These provisions became effective November 21, 1998. This series was initiated in October 2000. The standard protocol recommended by the International Federation for Family Health (IFFH) is followed. Information on patients is recorded on forms suggested by IFFG to accomplish good post-marketing surveillance. The potential role of uterine septae in WS failures is of particular interst to this investigator. Seven cases have been completed. There have been no failures. Side effects have been minor. Women have been exceptionally happy with this method. The Florida Agency for Health Care Administration has examined WS and found it to be an acceptable off-label use of quinacrine. Preliminary results have been similar to those reported by QS researchers around the world.